Removing hemp from the federal narcotics Schedule 1 list does not mean that all CBD products are now permitted, the US Food and Drug Administration (FDA) has warned.
Following passage of the Farm Bill which deschedules hemp, FDA commissioner Scott Gottlieb said that “increasing public interest in [cannabis-derived] products makes it even more important…for the FDA to clarify its regulatory authority over these products”.
That authority would continue to be exercised over food and drugs “regardless of the source of the substance, including whether the substance is derived from a plant that is classified as hemp under the Agriculture Improvement Act”, he said.
Before joining ECigIntelligence in early 2014 as one of its first employees, Barnaby had a 30-year career as a reporter and editor for newspapers, magazines and online services, working in Canada, the US and the Middle East as well as his current British location. He has edited publications covering fields including technology and the advertising industry, and was launch editor of the first large daily online news service in the British regional media. Barnaby also writes on classical music and film for a number of publications.
Barnaby manages the editorial and reporting teams and works closely with the analyst teams, to ensure that all content meets high standards of quality and relevance. He also writes for the site occasionally, mostly on science-related issues, and is a member of the Association of British Science Writers.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
"*" indicates required fields
Start your FREE trial
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
LATEST ALERTS
Removing hemp from the federal narcotics Schedule 1 list does not mean that all CBD products are now permitted, the US Food and Drug Administration (FDA) has warned.
